Douglas E. Onsi has shown a remarkable engagement in Leap Therapeutics' stock, with his holdings reaching peaks worth around $10 million in the early months of 2021. Since becoming CEO, he has negotiated favorable insider trading moves, reflecting confidence in...
Douglas E. Onsi has shown a remarkable engagement in Leap Therapeutics' stock, with his holdings reaching peaks worth around $10 million in the early months of 2021. Since becoming CEO, he has negotiated favorable insider trading moves, reflecting confidence in Leap's trajectory. Notably, from 2019 to now, there have been significant fluctuations in his trading activities, with the highest values registered above $10 million in 2021 alone. In recent years, this value has decreased, reflecting the ups and downs often faced in the biopharmaceutical sector. As of 2023, his trading activities have tapered, indicating potential shifts in strategy or immediate financial landscapes yet holding onto substantial residual equity value. Overall, his holdings display an ongoing investment in Leap's potential and a commitment to its long-term success.